HilleVax (NASDAQ:HLVX) Shares Down 0.5% - Here's Why

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) shares fell 0.5% during mid-day trading on Monday . The stock traded as low as $2.03 and last traded at $2.05. 85,273 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 465,548 shares. The stock had previously closed at $2.06.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "neutral" rating and issued a $2.00 target price on shares of HilleVax in a research report on Monday, March 31st. Six research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $3.00.

HilleVax Trading Down 0.5%

The company has a fifty day simple moving average of $1.93 and a 200-day simple moving average of $1.85. The stock has a market cap of $102.79 million, a price-to-earnings ratio of -0.95 and a beta of 0.76.

HilleVax (NASDAQ:HLVX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.25. As a group, analysts anticipate that HilleVax, Inc. will post -2.64 earnings per share for the current year.

Institutional Investors Weigh In On HilleVax

Several hedge funds have recently modified their holdings of HLVX. Millennium Management LLC lifted its position in HilleVax by 59.6% in the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company's stock worth $852,000 after purchasing an additional 153,815 shares during the period. Two Sigma Advisers LP raised its stake in HilleVax by 76.8% during the fourth quarter. Two Sigma Advisers LP now owns 41,200 shares of the company's stock worth $85,000 after acquiring an additional 17,900 shares in the last quarter. Takeda Pharmaceutical Co. Ltd. acquired a new position in HilleVax during the fourth quarter worth $13,919,000. Bank of Montreal Can raised its stake in HilleVax by 47.1% during the fourth quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock worth $74,000 after acquiring an additional 11,459 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in HilleVax during the fourth quarter worth $26,000. 86.42% of the stock is owned by institutional investors.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.